Strategy for Unknowns in SUS: Tiered ID and Toxicology



Strategy for Unknowns in SUS: Tiered ID and Toxicology

Published on 09/12/2025

Strategy for Unknowns in SUS: Tiered ID and Toxicology

Understanding the complexities associated with extractables and leachables (E&L) analysis is critical for professionals involved in the validation of single-use systems (SUS) within the pharmaceutical industry. This guide provides a comprehensive step-by-step approach for developing a strategy to address unknowns in SUS, with an emphasis on tiered identification (ID) and toxicology. This article serves professionals aiming to ensure compliance with regulations from the FDA, EMA,

and MHRA while enhancing patient safety and product efficacy.

Understanding Extractables and Leachables

Extractables are substances that can be extracted from materials under extreme conditions, while leachables refer to compounds that migrate from packaging or delivery systems into a pharmaceutical product during normal storage and use conditions. E&L studies are essential to assess the safety and compatibility of packaging materials with drug formulations, especially when it involves single-use systems.

The relevance of understanding E&L in the context of SUS cannot be overstated. Single-use systems, including filters, bags, and other components, have become increasingly popular in pharmaceutical manufacturing due to their ability to reduce cross-contamination risks and eliminate the need for cleaning validation. However, the introduction of these materials necessitates stringent evaluation under current Good Manufacturing Practice (cGMP) standards and guidelines as set forth in EU GMP Annex 1.

Regulatory Considerations for E&L Analysis

Regulatory bodies, including the FDA and EMA, provide guidance regarding the evaluation of E&L in materials that come into contact with pharmaceuticals. These guidelines emphasize the importance of conducting a risk assessment and implementing a scientifically sound approach to characterizing extractables. The Pharmaceutical Quality Research Institute (PQRI) has also developed guidelines addressing E&L testing protocols which focus on establishing an analytical evaluation threshold (AET) and a dose-based threshold (DBT).

  • **Analytical Evaluation Threshold (AET)**: This defines the concentration at which extractables and leachables can be considered insignificant with respect to patient safety and product quality.
  • **Dose-Based Threshold (DBT)**: The DBT is derived from toxicological data and provides a concentration threshold based on the intended use of the product.

Developing a strategy that integrates AET and DBT calculations is imperative in achieving a comprehensive understanding of the safety profile of SUS in the pharmaceutical context.

Step 1: Conduct an E&L Risk Assessment

Before diving into specific testing or analysis, it is essential to conduct a thorough risk assessment. This process elucidates the potential risks associated with the materials used in single-use systems. The following steps should be carried out:

  • Identify Materials Used: Catalog the materials in your single-use systems and assess their potential for extractables and leachables. Common materials in SUS may include polymers, additives, and adhesives.
  • Evaluate Historical Data: Review previous studies and literature associated with the materials in question. This includes analyzing any existing data on extractables from similar materials, thus informing your risk assessment.
  • Determine Volatility and Solubility: Assess the chemical properties such as volatility and solubility of each material to predict their potential migration into drug products.

This assessment establishes a foundational understanding which is essential for determining the necessity and type of subsequent testing.

Step 2: Develop a Testing Strategy

Once the E&L risk assessment has been conducted, the next step is to develop a tiered testing strategy. This includes selecting appropriate analytical methods and determining an effective testing protocol that aligns with regulatory standards.

In establishing a testing strategy, consider the following:

  • Screening Tests: Start with a preliminary screen to identify bulk extractables using techniques such as Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Mass Spectrometry (LC-MS). This step helps identify potential unknowns that necessitate further investigation.
  • Quantification of Extractables: Quantify the identified extractables to determine their concentrations compared to the established AET and DBT thresholds.
  • Tiered Identification Process: Develop a systematic approach to identification that includes both targeted and non-targeted methods. For unknowns, employ advanced techniques such as High-Resolution Mass Spectrometry (HRMS) for comprehensive profiling.

This strategy aims to ensure that all potential extractables are systematically evaluated, thus minimizing uncertainty regarding the safety profile of the products.

Step 3: Perform Toxicological Assessment

Upon identification and quantification of extractables and leachables, it is crucial to perform a toxicological assessment. This assessment evaluates the safety of identified chemicals and helps in making informed decisions about their acceptable limits in pharmaceutical products.

The process can be delineated into the following components:

  • Data Compilation: Compile toxicological data from reputable sources such as the National Toxicology Program or other databases specific to pharmaceuticals. This data should encompass the potential effects of the identified extractables.
  • Risk Characterization: Using this data, characterize the risk associated with each identified leachable. Determine if any of the substances exceed established AET or DBT thresholds based on their toxic profiles.
  • Iterative Review: Conduct iterative reviews as new toxicological information becomes available or as regulations evolve. This aids in maintaining compliance with guidelines from governing bodies like the FDA or EMA.

Consequently, the toxicological assessment is not only crucial for ensuring patient safety but also serves as a defender during inspections or audits by regulatory agencies.

Step 4: Implement Container Closure Integrity (CCI) Testing

Container Closure Integrity (CCI) testing is essential for verifying that single-use systems maintain the sterility and integrity of the drug product throughout its shelf life. The specifications for CCI are outlined in the USP Chapter 1207 on CCI.

In connection with E&L testing, CCI must be evaluated as follows:

  • Selection of CCI Methodology: Assess the most suitable testing methodologies such as dye penetration, helium leak testing, or vacuum decay tests based on the system’s design and intended use.
  • Establish Validation Protocols: Create detailed validation protocols that describe testing conditions, acceptance criteria, and responsibilities.
  • Ongoing Monitoring: Set up a process for ongoing monitoring of CCI to ensure continued compliance and effectiveness throughout the life cycle of the product.

Adhering to rigorous CCI testing not only bolsters product integrity but also assures compliance with cGMP practices and facilitates regulatory submissions.

Step 5: Documentation and Compliance

Robust documentation practices are essential for demonstrating compliance with E&L testing procedures and toxicological assessments. Adequately documenting each step of the process provides a solid basis for regulatory submissions and future audits.

  • Maintain Comprehensive Records: Documentation should include risk assessment records, testing methodologies, raw data from analytical testing, and toxicological assessments.
  • Develop Validation Reports: Create comprehensive validation reports summarizing the findings from E&L studies, including methodologies, results, risk assessments, and CCI evaluations.
  • Review and Revision Control: Implement procedures to review and amend documentation in light of new findings or regulatory updates, ensuring that compliance is maintained continuously.

Such diligent record-keeping is vital for maintaining quality assurance as well as satisfying regulatory expectations.

Conclusion and Future Directions

The strategic approach outlined herein serves as a framework for addressing unknowns associated with single-use systems, focusing on extractables and leachables. Regulatory compliance is paramount, and the evolving landscape of pharmaceutical manufacturing necessitates a proactive approach to E&L risk assessment, testing, toxicology evaluations, CCI testing, and comprehensive documentation practices.

By implementing these methodologies, pharmaceutical professionals can ensure that their products not only meet current regulatory standards but also prioritize patient safety and product integrity. As regulations evolve, remaining attentive and adaptable is key to navigating the complexities of E&L analysis within the context of single-use systems.